Skip to main content
Clinical Trials/NCT01176721
NCT01176721
Completed
Phase 2

Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia: a Randomized, Controlled, Double Blind, Two-armed Clinical Trial

cerbomed GmbH2 sites in 1 country20 target enrollmentMarch 2010
ConditionsSchizophrenia

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
cerbomed GmbH
Enrollment
20
Locations
2
Primary Endpoint
Safety and efficacy of t-VNS in schizophrenia
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.

Study hypothesis: t-VNS may improve negative symptoms, depressive symptoms, cognitive impairment,and aggressive behavior of treated schizophrenia patients.

Registry
clinicaltrials.gov
Start Date
March 2010
End Date
February 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
cerbomed GmbH
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of a schizophrenic disorder (F20 according to ICD-10),duration of disease ≥ 12 months
  • Appliance of the t-VNS® medical device according to the manual

Exclusion Criteria

  • Improvent of the PANSS score within the period of 2 - 4 weeks from screening to the baseline
  • Pregnancy
  • Bronchial asthhma in medical history
  • clinically relevant internistic, neurological or psychiatric diseases
  • abuse of drugs or alcohol until 4 weeks to enrollment
  • Traumatic brain injury in medical history as well as invasive and non-invasive methods of treatment (e.g. tumor surgery (Gammma knife surgery))
  • indication of structural impairment of the basal ganglia or the brain stem
  • malformations of the pinna
  • further circumstances that at the discretion of the investigator will not allow to include the subject into the clinical study

Outcomes

Primary Outcomes

Safety and efficacy of t-VNS in schizophrenia

Time Frame: 24 weeks

Secondary Outcomes

  • Recording of clinical performance of t-VNS in schizophrenia(24 weeks)

Study Sites (2)

Loading locations...

Similar Trials